Eblasakimab Monthly Dosing Shows Potential for Best-In-Class Therapy in Positive Phase 2b Study in Atopic Dermatitis
ASLNDelisted Stock | USD 0.60 0.03 4.76% |
About 62% of Aslan Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in Aslan Pharmaceuticals suggests that many traders are alarmed regarding Aslan Pharmaceuticals' prospects. Aslan Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Aslan Pharmaceuticals. Many technical investors use Aslan Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Aslan |
Eblasakimab is the first biologic in moderate-to-severe atopic dermatitis to demonstrate a competitive efficacy profile with once-monthly dosing from...
Read at globenewswire.com
Aslan Pharmaceuticals Fundamental Analysis
We analyze Aslan Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aslan Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aslan Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Short Ratio
Short Ratio Comparative Analysis
Aslan Pharmaceuticals is currently under evaluation in short ratio category among its peers. Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Aslan Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Aslan Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Aslan Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Aslan Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Aslan Pharmaceuticals Related Equities
CTMX | CytomX Therapeutics | 12.84 | ||||
LYRA | Lyra Therapeutics | 10.53 | ||||
ANEB | Anebulo Pharmaceuticals | 7.64 | ||||
ADAG | Adagene | 6.39 | ||||
NAMS | NewAmsterdam Pharma | 1.73 | ||||
ACRV | Acrivon Therapeutics, | 0.13 | ||||
AGIO | Agios Pharm | 0.02 | ||||
IVA | Inventiva | 0.38 | ||||
ACHL | Achilles Therapeutics | 0.93 | ||||
AVTE | Aerovate Therapeutics | 1.50 | ||||
GPCR | Structure Therapeutics | 2.03 | ||||
ASMB | Assembly Biosciences | 2.09 | ||||
CMPX | Compass Therapeutics | 2.41 | ||||
CGEM | Cullinan Oncology | 2.81 | ||||
TIL | Instil Bio | 2.86 | ||||
GLUE | Monte Rosa | 3.52 | ||||
IOBT | IO Biotech | 4.44 | ||||
MLYS | Mineralys Therapeutics, | 4.60 | ||||
ERAS | Erasca | 4.95 | ||||
ANTX | AN2 Therapeutics | 6.25 |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Other Consideration for investing in Aslan Stock
If you are still planning to invest in Aslan Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aslan Pharmaceuticals' history and understand the potential risks before investing.
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |